Emergency Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Medical Intensive Care Unit, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
J Cardiothorac Vasc Anesth. 2023 Jan;37(1):73-80. doi: 10.1053/j.jvca.2022.09.084. Epub 2022 Sep 20.
Tracheostomy usually is performed to aid weaning from mechanical ventilation and facilitate rehabilitation and secretion clearance. Little is known about the safety of percutaneous tracheostomy in patients with severe COVID-19 supported on venovenous extracorporeal membrane oxygenation (VV-ECMO). This study aimed to investigate the bleeding risk of bedside percutaneous tracheostomy in patients with COVID-19 infection supported with VV-ECMO.
A Retrospective review of electronic data for routine care of patients on ECMO.
Tertiary, university-affiliated national ECMO center.
Patients with COVID-19 who underwent percutaneous tracheostomy while on VV-ECMO support.
No intervention was conducted during this study.
Electronic medical records of 16 confirmed patients with COVID-19 who underwent percutaneous tracheostomy while on VV-ECMO support, including patient demographics, severity of illness, clinical variables, procedural complications, and outcomes, were compared with 16 non-COVID-19 patients. The SPSS statistical software was used for statistical analysis. The demographic data were compared using the chi-square test, and normality assumption was tested using the Shapiro-Wilk test. The indications for tracheostomy in all the patients were prolonged mechanical ventilation and sedation management. None of the patients suffered a life-threatening procedural complication within 48 hours. Moderate-to-severe bleeding was similar in both groups. There was no difference in 30- and 90-days mortality between both groups. As per routine screening results, none of the staff involved contracted COVID-19 infection.
In this case series, percutaneous tracheostomy during VV-ECMO in patients with COVID-19 appeared to be safe and did not pose additional risks to patients or healthcare workers.
气管切开术通常用于辅助机械通气撤机,并促进康复和分泌物清除。对于接受静脉-静脉体外膜肺氧合(VV-ECMO)支持的重症 COVID-19 患者,经皮气管切开术的安全性知之甚少。本研究旨在探讨 VV-ECMO 支持下 COVID-19 感染患者床边经皮气管切开术的出血风险。
对 ECMO 常规护理的电子数据进行回顾性分析。
三级、大学附属国家 ECMO 中心。
接受 VV-ECMO 支持的 COVID-19 患者行经皮气管切开术。
本研究期间未进行任何干预。
对 16 例接受 VV-ECMO 支持的 COVID-19 患者行经皮气管切开术的电子病历,包括患者人口统计学、疾病严重程度、临床变量、程序并发症和结局,并与 16 例非 COVID-19 患者进行比较。使用 SPSS 统计软件进行统计分析。使用卡方检验比较人口统计学数据,使用 Shapiro-Wilk 检验检验正态性假设。所有患者行气管切开术的指征均为机械通气时间延长和镇静管理。所有患者在 48 小时内均未发生危及生命的程序并发症。两组的中重度出血情况相似。两组患者 30 天和 90 天死亡率无差异。根据常规筛查结果,无工作人员感染 COVID-19。
在本病例系列中,VV-ECMO 期间对 COVID-19 患者行经皮气管切开术似乎是安全的,不会给患者或医护人员带来额外风险。